Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1987 Jul;128(1):52–60.

In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma. Relation to prognostic parameters.

T An, U Sood, T Pietruk, G Cummings, K Hashimoto, J D Crissman
PMCID: PMC1899793  PMID: 3496796

Abstract

The authors examined inflammatory mononuclear cells in 10 fibroadenomas and 56 ductal infiltrating type carcinomas of the breast to see whether the distribution of various subpopulations of the mononuclear cells were correlated with known histologic, biochemical, and clinical parameters of the cancers. T cells, B cells, natural killer cells, and macrophages were quantitated on frozen tissue sections, which were stained with monoclonal antibodies, as demonstrated by the immunoperoxidase technique. The carcinomas had significantly higher numbers of T cells, Leu-3+ helper-inducer cells, T8+ cytotoxic-suppressor cells, M5+ macrophages, and T6+ Langerhans cells than the fibroadenomas. There were no significant differences in the distribution of natural killer cells. Among these mononuclear subsets, helper-inducer T cells were the primary cell type in both benign and malignant neoplasms. Estrogen receptor-positive carcinoma had significantly fewer numbers of T cells and the subgroup of Leu-3+ helper-inducer cells. Clinical Stage 3 cancers had significantly fewer numbers of T cells and natural killer cells than both fibroadenomas and Stage I and II neoplasms. Prominent infiltration of T cells, specifically helper-inducer cells, is not associated with estrogen receptor positivity, which is known to be a favorable prognostic marker of breast carcinoma. The findings of fewer T cells and natural killer cells in Stage 3 carcinomas are intriguing but unexplained.

Full text

PDF
52

Images in this article

54Figure 1
on p.54
55Figure 2
on p.55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler A., Stein J. A., Ben-Efraim S. Immunocompetence, immunosuppression, and human breast cancer. II. Further evidence of initial immune impairment by integrated assessment effect of nodal involvement (N) and of primary tumor size (T). Cancer. 1980 Apr 15;45(8):2061–2073. doi: 10.1002/1097-0142(19800415)45:8<2061::aid-cncr2820450813>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  2. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berg J. W. Morphological evidence for immune response to breast cancer. An historical review. Cancer. 1971 Dec;28(6):1453–1456. doi: 10.1002/1097-0142(197112)28:6<1453::aid-cncr2820280618>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  4. Bhan A. K., DesMarais C. L. Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer. J Natl Cancer Inst. 1983 Sep;71(3):507–516. [PubMed] [Google Scholar]
  5. Bishop H. M., Blamey R. W., Elston C. W., Haybittle J. L., Nicholson R. I., Griffiths K. Relationship of oestrogen-receptor status to survival in breast cancer. Lancet. 1979 Aug 11;2(8137):283–284. doi: 10.1016/s0140-6736(79)90295-2. [DOI] [PubMed] [Google Scholar]
  6. Black M. M., Barclay T. H., Hankey B. F. Prognosis in breast cancer utilizing histologic characteristics of the primary tumor. Cancer. 1975 Dec;36(6):2048–2055. doi: 10.1002/cncr.2820360919. [DOI] [PubMed] [Google Scholar]
  7. Chabon A. B., Goldberg J. D., Venet L. Carcinoma of the breast: interrelationships among histopathologic features, estrogen receptor activity, and age of the patient. Hum Pathol. 1983 Apr;14(4):368–372. doi: 10.1016/s0046-8177(83)80124-5. [DOI] [PubMed] [Google Scholar]
  8. Champion H. R., Wallace I. W., Prescott R. J. Histology in breast cancer prognosis. Br J Cancer. 1972 Apr;26(2):129–138. doi: 10.1038/bjc.1972.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Crissman J. D. Tumor-host interactions as prognostic factors in the histologic assessment of carcinomas. Pathol Annu. 1986;21(Pt 1):29–52. [PubMed] [Google Scholar]
  10. Cunningham-Rundles S., Filippa D. A., Braun D. W., Jr, Antonelli P., Ashikari H. Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women. J Natl Cancer Inst. 1981 Sep;67(3):585–590. [PubMed] [Google Scholar]
  11. Eremin O., Ashby J., Stephens J. P. Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignant disease. Int J Cancer. 1978 Jan 15;21(1):35–41. doi: 10.1002/ijc.2910210108. [DOI] [PubMed] [Google Scholar]
  12. Fisher E. R., Redmond C. K., Liu H., Rockette H., Fisher B. Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer. 1980 Jan 15;45(2):349–353. doi: 10.1002/1097-0142(19800115)45:2<349::aid-cncr2820450226>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  13. Fulton A., Heppner G., Roi L., Howard L., Russo J., Brennan M. Relationship of natural killer cytotoxicity to clinical and biochemical parameters of primary human breast cancer. Breast Cancer Res Treat. 1984;4(2):109–116. doi: 10.1007/BF01806393. [DOI] [PubMed] [Google Scholar]
  14. Furmanski P., Saunders D. E., Brooks S. C., Rich M. A. The prognostic value of estrogen receptor determinations in patients with primary breast cancer: an update. Cancer. 1980 Dec 15;46(12 Suppl):2794–2796. doi: 10.1002/1097-0142(19801215)46:12+<2794::aid-cncr2820461410>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  15. Giorno R. Mononuclear cells in malignant and benign human breast tissue. Arch Pathol Lab Med. 1983 Aug;107(8):415–417. [PubMed] [Google Scholar]
  16. Hamlin I. M. Possible host resistance in carcinoma of the breast: a histological study. Br J Cancer. 1968 Sep;22(3):383–401. doi: 10.1038/bjc.1968.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hammar S. P., Bockus D., Remington F., Hallman K. O., Winterbauer R. H., Hill L. D., Bauermeister D. E., Jones H. W., Mennemeyer R. P., Wheelis R. F. Langerhans cells and serum precipitating antibodies against fungal antigens in bronchioloalveolar cell carcinoma: possible association with pulmonary eosinophilic granuloma. Ultrastruct Pathol. 1980 Jan-Mar;1(1):19–37. doi: 10.3109/01913128009141392. [DOI] [PubMed] [Google Scholar]
  18. Herberman R. B., Djeu J., Kay H. D., Ortaldo J. R., Riccardi C., Bonnard G. D., Holden H. T., Fagnani R., Santoni A., Puccetti P. Natural killer cells: characteristics and regulation of activity. Immunol Rev. 1979;44:43–70. doi: 10.1111/j.1600-065x.1979.tb00267.x. [DOI] [PubMed] [Google Scholar]
  19. Hsu S. M., Cossman J., Jaffe E. S. Lymphocyte subsets in normal human lymphoid tissues. Am J Clin Pathol. 1983 Jul;80(1):21–30. doi: 10.1093/ajcp/80.1.21. [DOI] [PubMed] [Google Scholar]
  20. Knight W. A., Livingston R. B., Gregory E. J., McGuire W. L. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977 Dec;37(12):4669–4671. [PubMed] [Google Scholar]
  21. Knowles D. M., 2nd, Tolidjian B., Marboe C., D'Agati V., Grimes M., Chess L. Monoclonal anti-human monocyte antibodies OKM1 and OKM5 possess distinctive tissue distributions including differential reactivity with vascular endothelium. J Immunol. 1984 May;132(5):2170–2173. [PubMed] [Google Scholar]
  22. Lauder I., Aherne W., Stewart J., Sainsbury R. Macrophage infiltration of breast tumours: a prospective study. J Clin Pathol. 1977 Jun;30(6):563–568. doi: 10.1136/jcp.30.6.563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Millis R. R. Correlation of hormone receptors with pathological features in human breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2869–2871. doi: 10.1002/1097-0142(19801215)46:12+<2869::aid-cncr2820461426>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  24. Murphy G. F., Bhan A. K., Sato S., Harrist T. J., Mihm M. C., Jr Characterization of Langerhans cells by the use of monoclonal antibodies. Lab Invest. 1981 Nov;45(5):465–468. [PubMed] [Google Scholar]
  25. Ridolfi R. L., Rosen P. P., Port A., Kinne D., Miké V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977 Oct;40(4):1365–1385. doi: 10.1002/1097-0142(197710)40:4<1365::aid-cncr2820400402>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  26. Roses D. F., Bell D. A., Flotte T. J., Taylor R., Ratech H., Dubin N. Pathologic predictors of recurrence in stage 1 (TINOMO) breast cancer. Am J Clin Pathol. 1982 Dec;78(6):817–820. doi: 10.1093/ajcp/78.6.817. [DOI] [PubMed] [Google Scholar]
  27. Rowe D. J., Beverley P. C. Characterisation of breast cancer infiltrates using monoclonal antibodies to human leucocyte antigens. Br J Cancer. 1984 Feb;49(2):149–159. doi: 10.1038/bjc.1984.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Schoorl R., Riviere A. B., Borne A. E., Feltkamp-Vroom T. M. Identification of T and B lymphocytes in human breast cancer with immunohistochemical techniques. Am J Pathol. 1976 Sep;84(3):529–544. [PMC free article] [PubMed] [Google Scholar]
  29. Shimokawara I., Imamura M., Yamanaka N., Ishii Y., Kikuchi K. Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: an immunoperoxidase study with anti-human T- and B-cell sera. Cancer. 1982 Apr 1;49(7):1456–1464. doi: 10.1002/1097-0142(19820401)49:7<1456::aid-cncr2820490724>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  30. Takasugi M., Ramseyer A., Takasugi J. Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression. Cancer Res. 1977 Feb;37(2):413–418. [PubMed] [Google Scholar]
  31. Underwood J. C. Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br J Cancer. 1974 Dec;30(6):538–548. doi: 10.1038/bjc.1974.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Vollenweider-Zerargui L., Barrelet L., Wong Y., Lemarchand-Béraud T., Gómez F. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer. 1986 Mar 15;57(6):1171–1180. doi: 10.1002/1097-0142(19860315)57:6<1171::aid-cncr2820570618>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  33. Vose B. M., Moore M. Suppressor cell activity of lymphocytes infiltrating human lung and breast tumours. Int J Cancer. 1979 Nov 15;24(5):579–585. doi: 10.1002/ijc.2910240510. [DOI] [PubMed] [Google Scholar]
  34. Vose B. M., Vánky F., Klein E. Human tumour--lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour-infiltrating, blood and lymph-node lymphocytes with autologous tumour cells. Int J Cancer. 1977 Dec 15;20(6):895–902. doi: 10.1002/ijc.2910200612. [DOI] [PubMed] [Google Scholar]
  35. Watanabe S., Sato Y., Kodama T., Shimosato Y. Immunohistochemical study with monoclonal antibodies on immune response in human lung cancers. Cancer Res. 1983 Dec;43(12 Pt 1):5883–5889. [PubMed] [Google Scholar]
  36. Whitwell H. L., Hughes H. P., Moore M., Ahmed A. Expression of major histocompatibility antigens and leucocyte infiltration in benign and malignant human breast disease. Br J Cancer. 1984 Feb;49(2):161–172. doi: 10.1038/bjc.1984.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wolff K., Stingl G. The Langerhans cell. J Invest Dermatol. 1983 Jun;80 (Suppl):17s–21s. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES